AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05586360
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg taken orally daily for 8 weeks
Trial: NCT05740813
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo is administered orally once per day for 24 weeks.
Trial: NCT05678010
Drug: AZD1390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
Trial: NCT05829187
Drug: Momordica Charantia Extract
RxNorm normalized name: Momordica charantia stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momordica charantia extract capsules at a dose of 325 mg were given to patients for 3 days
Trial: NCT05132582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally twice daily
Trial: NCT05198310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06524830
Drug: VLS-01-BU Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo buccal transmucosal administration
Trial: NCT04843852
Drug: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
RxNorm normalized name: Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 0.5ml intramuscular injection on day 0 and week 4.
Trial: NCT05832827
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
Trial: NCT06224530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
Trial: NCT06213857
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An immunosuppressive medication that is used for the treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis). It works by decreasing the activity of the body's immune system so it will not attack itself.
Trial: NCT05755386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Trial: NCT05403827
Drug: K-161
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-161 Ophthalmic Solution
Trial: NCT05403827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Solution
Trial: NCT06022822
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05805358
Drug: Hyperpolarized 13C-Pyruvate injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
Trial: NCT05565092
Drug: ALXN1820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1820 will be administered subcutaneously.
Trial: NCT04569435
Drug: ANX005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT05774873
Drug: IBI334 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Trial: NCT05774873
Drug: IBI334 F
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Trial: NCT06280703
Drug: LY3938577
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Intravenously (IV)
Trial: NCT06280703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Intravenously (IV)
Trial: NCT06280703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT05166161
Drug: PTC923
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
Trial: NCT05373433
Drug: SSD8432 750mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID
Trial: NCT05373433
Drug: SSD8432 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID
Trial: NCT06452433
Drug: gumarontinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg , qd ,po, expect 6 months.
Trial: NCT06452433
Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the actual situation of patients. Take as recommended, expect 6 months.
Trial: NCT00117065
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04877288
Drug: Enteric Coated Mycophenolate Sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04877288
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on Specified days
Trial: NCT04625283
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo arm will receive intraoperative and postoperative saline.
Trial: NCT04823585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution. Subcutaneous.
Trial: NCT05145309
Drug: KMgCit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement that provide K, Mg, and citrate
Trial: NCT05145309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Power with identical appearance to KMgCit
Trial: NCT06066515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly subcutaneous injection
Trial: NCT05245396
Drug: Ref (TF2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
Trial: NCT06108050
Drug: JZP898
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug monotherapy
Trial: NCT06422936
Drug: BO-112
RxNorm normalized name: BOS TAURUS EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
Trial: NCT06441630
Drug: AD-227B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Trial: NCT06441630
Drug: AD-227C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Trial: NCT06441630
Drug: Placebo of AD-227B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per Oral, 1 Tablet, Once a day for 8 weeks
Trial: NCT06588855
Drug: RO7790121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
Trial: NCT06588855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching IV RO7790121. Placebo matching SC RO7790121.
Trial: NCT05178043
Drug: GT90001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GT90001 7mg/kg to be administered as an intravenous infusion every 2 weeks (Q2W) after Nivolumab infusion.
Trial: NCT05378893
Drug: DR10624 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered via subcutaneous injection
Trial: NCT05378893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered via subcutaneous injection
Trial: NCT04682691
Drug: Erythromycin (400mg)
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Erythromycin (400mg)
Trial: NCT06497036
Drug: GP404141
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT04841434
Drug: Voraxaze Injectable Product
RxNorm normalized name: Voraxaze Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to \<40 mL/min, or in the case of decreased GFR, the decrease is \>50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing \>100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
Trial: NCT03923322
Drug: Botanical Tincture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
Trial: NCT05364671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
Trial: NCT05775965
Drug: acetylsalicylic acid (ASA) 81mg Oral Tablet
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
Trial: NCT04795726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
Trial: NCT06770530
Drug: Isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline solution, single dose 200 ml
Trial: NCT06773962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion.
Trial: NCT05156710
Drug: BIVV020 (SAR445088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
Trial: NCT05156710
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Form: Vary Route of Administration: Vary
Trial: NCT05761366
Drug: Al18F-PSMA-BCH PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
Trial: NCT00240864
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240864
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06263673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
Trial: NCT06289647
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
Trial: NCT06450210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
Trial: NCT06087536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
Trial: NCT06530290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once a day, for 12 weeks
Trial: NCT06529796
Drug: IXP
RxNorm normalized name: NovoSeven RT with MixPro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT06454188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg tablet once per day.
Trial: NCT05730816
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of normal saline.
Trial: NCT04891731
Drug: AI or TAM
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
Trial: NCT04868045
Drug: levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning.
Trial: NCT05915013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT05463367
Drug: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
RxNorm normalized name: carbidopa-levodopa 25 mg-100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Trial: NCT05463367
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of naproxen 500mg alongside carbidopa/levodopa, when applicable.This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Trial: NCT05463367
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be pre-screened in regards to their opioid medication. They will receive a single dose of their opioid dose, when appropriate. This will be double-blinded, as neither participants nor study staff will know what medication the participant is receiving.
Trial: NCT06040268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA134a inhaler
Trial: NCT04767373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride \[NaCL\]) solution
Trial: NCT04485104
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT05064488
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive rosuvastatin tablet under fed conditions, once a day on Day 1 and Day 10 in Part 1.
Trial: NCT06218303
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
Trial: NCT05231785
Drug: ALN-APP
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ALN-APP will be administered intrathecally (IT)
Trial: NCT05231785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered IT
Trial: NCT05626010
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 1g iv dripping at end of surgery
Trial: NCT05626010
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 300mg iv dripping at end of surgery
Trial: NCT05974410
Drug: AVM0703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small molecule immunomodulatory drug
Trial: NCT05974410
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: physiologic circadian glucocorticoid
Trial: NCT05974410
Drug: Proton pump inhibitor
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05896137
Drug: CS0159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QD
Trial: NCT06060782
Drug: Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days
Trial: NCT05879822
Drug: INCB099280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm description
Trial: NCT05030545
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
Trial: NCT06274905
Drug: Aqueous cream BP
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous cream
Trial: NCT04830644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice a day
Trial: NCT00000626
Drug: Doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05702073
Drug: INS068 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Trial: NCT05035641
Drug: AND017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
Trial: NCT05035641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, 3 times per week
Trial: NCT04668222
Drug: Yu-Ping-Feng formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yu-Ping-Feng formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08255). The intake dosage is 5g twice daily.
Trial: NCT05794243
Drug: LY3493269
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05794243
Drug: Salcaprozate Sodium (SNAC)
RxNorm normalized name: salcaprozate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04668222
Drug: Xiang-Sha-Liu-Jun formula
RxNorm normalized name: Calagel Reformulated Jun 2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiang-Sha-Liu-Jun formula produced by PuraPharm International (H.K) Ltd is a registered Chinese medicine formula by Chinese Medicine Council of Hong Kong (registration number: HKC-08252). The intake dosage is 5g twice daily.
Trial: NCT04668222
Drug: Placebo for Deficiency of Qi and Yang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the group of deficiency of Qi and Yang is composed of 5% Yu-Ping-Feng formula+Xiang-Sha-Liu-Jun formula
Trial: NCT04668222
Drug: Placebo for Deficiency of Qi and Yin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the group of deficiency of Qi and Yin is composed of 5% Yu-Ping-Feng formula+Liu-Wei-Di-Huang formula
Trial: NCT05274802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo before Breakfast
Trial: NCT05274802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of placebo up to two times daily
Trial: NCT05538247
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate release oral capsules 50 mg, 3 times a day for 6 days
Trial: NCT05538247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 250 mg capsules that contains no active study ingredient orally twice daily for 14 days